檢索結果 - Yiyun Tang
- Showing 1 - 11 results of 11
-
1
-
2
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK 由 Ugo De Giorgi, Stephen J. Freedland, Antti Rannikko, M. Backhaus, Arnauld Villers, Jamal Tarazi, Yiyun Tang, Gabriel P. Haas, Matt Rosales, Neal D. Shore
出版 2025Artigo -
3
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study 由 Pasi A. Jänne, Alice T. Shaw, D. Ross Camidge, Giuseppe Giaccone, S. Martin Shreeve, Yiyun Tang, Zelanna Goldberg, Jean‐François Martini, Huiping Xu, Leonard P. James, Benjamin Solomon
出版 2016Artigo -
4
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC 由 S.-H.I. Ou, Pasi A. Jänne, Cynthia Huang Bartlett, Yiyun Tang, D.-W. Kim, Gregory A. Otterson, Lucio Crinò, Paulina Selaru, D. P. Cohen, Jeffrey W. Clark, Gregory J. Riely
出版 2014Artigo -
5
Complex renal cysts associated with crizotinib treatment 由 Patrick Schnell, Cynthia Huang Bartlett, Benjamin Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso De Pas, S.D. Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Z. Safferman, Ji‐Youn Han
出版 2015Artigo -
6
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer 由 Yi‐Long Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Byoung Chul Cho, Chun‐Ming Tsai, Chin‐Hee Chung, Keith D. Wilner, Yiyun Tang, Elizabeth T. Masters, Paulina Selaru, Tony Mok
出版 2018Artigo -
7
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating... 由 Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu
出版 2020Artigo -
8
Crizotinib in Patients With MET-Amplified NSCLC 由 D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz
出版 2021Artigo -
9
1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK 由 Stephen J. Freedland, Martin Gleave, U.F.F. De Giorgi, Antti Rannikko, Christopher Pieczonka, Swetha Sridharan, Klaus Brasso, Henry H. Woo, Antonio Gómez‐Caamaño, Jeffery W. Saranchuk, L.T. Nordquist, Ubirajara Ferreira, Yiyun Tang, Brad Rosbrook, Gabriel P. Haas, M. Rosales, F. Zohren, Neal D. Shore
出版 2023Artigo -
10
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis 由 Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Gregory J. Riely, Justin F. Gainor, Jeffrey A. Engelman, Geoffrey I. Shapiro, Daniel B. Costa, Sai‐Hong Ignatius Ou, Mohit Butaney, Ravi Salgia, Robert G. Maki, Marileila Varella‐Garcia, Robert C. Doebele, Yung‐Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, A. John Iafrate, D. Ross Camidge
出版 2011Artigo -
11
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study 由 D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
出版 2012Artigo
相關主題
Internal medicine
Medicine
Lung cancer
Oncology
Crizotinib
Malignant pleural effusion
Cancer
ALK inhibitor
Gastroenterology
Adverse effect
Anaplastic lymphoma kinase
Confidence interval
Hazard ratio
Adenocarcinoma
Androgen receptor
Biology
Chemotherapy
Enzalutamide
Epidermal growth factor receptor
Gefitinib
Gene
Genetics
Gynecology
Phases of clinical research
Progression-free survival
Prostate cancer
ROS1
Randomized controlled trial
Response Evaluation Criteria in Solid Tumors
Retrospective cohort study